Benefitting From Immunotherapy in CRC
Pashtoon M. Kasi, MD, MBBS, MS, discusses the patient populations with colorectal cancer that are likely to benefit from immunotherapy treatment.
Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at the Mayo Clinic, discusses the populations of patients with colorectal cancer (CRC) that are likely to benefit from immunotherapy treatment.
Previously, immunotherapy was not an option for patients with CRC, but now subsets of patients has been identified that respond to this type of treatment, Kasi says. Patients who can benefit from immunotherapy include patients with mismatch repair deficient, microsatellite instability-high, or Lynch syndrome-associated CRC.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
